List of Radiopharmaceuticals/Radiotherapies Companies in Canada - 10

Founded in 2017, 48Hour Discovery (48HD) has a powerful technology platform for peptide-based drug discovery. We are reducing the cost, time, and risk of developing new therapies with our innovative target screening strategy to quickly identify the best and most promising drug leads.

Abdera Therapeutics Inc. is a precision oncology company developing next-generation targeted radiation therapies - one of the most cutting-edge and highly promising areas of drug development. The company is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells. Abdera is using this platform to enable the rapid development of a broad range of safe and efficacious therapies serving cancer patients with limited treatment options. Abdera Therapeutics is growing rapidly and seeking key new team members who thrive at the cutting-edge of innovation. Come join us and be a part of the ground-breaking team set to unlock the power of targeted radiotherapy!

Alpha Cancer Technologies Inc. (ACT) is a private clinical stage biotechnology company with platform technologies in Immunotherapy and Immuno-Oncology. These platforms under development treat auto-immune disease indications and cancer. The company’s drug products use our proprietary recombinant human alpha fetoprotein (AFP).

AtomVie Global Radiopharma Inc. is a contract development and manufacturing organization (CDMO) based in Hamilton, Ontario, Canada. Established in August 2022, the company specializes in the production of radiopharmaceuticals, focusing on both clinical and commercial applications. AtomVie is recognized for its Good Manufacturing Practice (GMP)-compliant production, drawing on over ten years of expertise from its predecessor, the Centre for Probe Development and Commercialization (CPDC). The company is expanding its capabilities with a new multi-product facility, set to significantly increase production capacity. AtomVie offers a range of services, including GMP manufacturing of radiotherapeutics and medical isotopes, regulatory support with a strong approval track record, and logistics management for the global distribution of short-lived radiopharmaceuticals. AtomVie serves over ten international pharmaceutical companies and supports clinical trials across more than 17 countries, emphasizing reliability in its production and logistics processes.

On June 6, 2024, AstraZeneca announced the successful completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments. This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs, including their most advanced programme, FPI-2265, a potential new treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), and brings new expertise and pioneering R&D, manufacturing and supply chain capabilities in actinium-based RCs to AstraZeneca. It also strengthens AstraZeneca’s presence in and commitment to Canada. As a result of the acquisition, Fusion has become a wholly owned subsidiary of AstraZeneca, with operations in Canada and the US. At Fusion, we are pushing the boundaries of science to create innovative precision medicines for cancer. We are a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals as precision medicines for the treatment of cancer. We have developed our Targeted Alpha Therapies, or TAT, platform together with our proprietary Fast-Clear™ linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the therapies to tumors.

POINT Biopharma develops next-generation radioligand therapies for the treatment of cancer. On Dec. 27, 2023, Lilly Completes Acquisition of POINT Biopharma.

Soricimed is a privately-held, clinical stage company dedicated to developing effective and novel targeted treatments for cancer. Since the discovery of a unique protein found in the venomous saliva of the northern short-tailed shrew in 2005, the company is committed to developing effective, highly targeted delivery peptides and powerful therapeutics for several types of solid tumour cancers, making an impact on those living with often devastating conditions. General Information and Guidelines: Soricimed strives to create informative and engaging online communities that share information in meaningful ways. We welcome and encourage your participation and engagement in thoughtful and respectful discourse.

Interested in working at Synex? Connect with us https://careers.synexmedical.com/ Our mission is to make predictive health a reality by providing accurate and non-invasive monitoring at the molecular level. Non-invasive glucose monitoring has been sought after for decades. Many people have tried. None have succeeded. Our novel approach to solving and going beyond this challenge will enable a future of true predictive healthcare. We’re looking for passionate and exceptionally talented people who want to be part of the team that achieves this vision.

Theralase® is focused on the design, development, manufacturing, and sale of patented laser technology platforms used in a wide range of bio-stimulative and bio-destructive applications. The company is a Canadian clinical stage pharmaceutical company dedicated to the research and development of light-activated Photo Dynamic Compounds (PDCs) for the treatment of various cancers. Theralase® was one of the first companies in North America to develop personalized anti-cancer therapy and cool laser therapy.

Voyageur Pharmaceuticals Ltd. | VM.TSX Voyageur Pharmaceuticals Ltd. is an entrepreneurial driven company headquartered in Canada, specializing in the development and manufacturing of natural based contrast agents for diagnostic imaging technologies. Our trading symbol is VM.TSX on the Toronto Venture Exchange, testament to our robust corporate positioning and transparent operations. Our primary offerings span across the realms of CT, Fluoroscopy, MRI, and Ultrasound imaging. We proudly source Barium and Iodine directly from the earth, rigorously purifying these minerals into Active Pharmaceutical Ingredients (APIs), before culminating the process in the creation of finished drug products. This complete, end-to-end production chain aligns seamlessly with our motto - "From the Earth to the Bottle". On the frontier of innovation, Voyageur Pharmaceuticals is also actively engaged in Fullerene drug development. This remarkable technology harnesses the potential of carbon capture through the Eden system, turning captured carbon into Fullerenes, thus laying the groundwork for a new, revolutionary drug development program. Our operations are rooted in a scientific and drug-oriented focus, keeping patient well-being and improved diagnostic accuracy at the heart of our mission. Committed to excellence and innovation, Voyageur Pharmaceuticals Ltd. is not just about mining resources; it's about mining the future of healthcare. We invite you to connect with us, be part of our story, and explore the boundless opportunities that lie at the intersection of nature, science, and technology.